The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.

Top 5 Upgrades:

• Rosenblatt upgraded Zscaler (ZS) to Buy from Neutral with a $235 price target after the company's "strong" Q2 report.
• Susquehanna upgraded Caesars (CZR) to Neutral from Negative with an unchanged price target of $30. The firm no longer sees an actionable short with the shares now close to its price target.
• KeyBanc upgraded CubeSmart (CUBE) to Overweight from Sector Weight with a $47 price target. The firm cites the company's gradually improving operating fundamentals year-to-date, with both occupancy and move-in rent growth demonstrating early signs of stabilization, and "relatively conservative" for the upgrade.
• Seaport Research upgraded five homebuilder stocks to Buy - raising KB Home (KBH) with a $79 price target, Lennar (LEN) with a $154 price target, TRI Pointe (TPH) with a $41 price target, M/I Homes (MHO) with a $151 price target and D.R. Horton (DHI) with a $164 price target - while also upgrading Meritage Homes (MTH), Taylor Morrison (TMHC) and PulteGroup (PHM) all to Neutral. Within "a highly correlated sector," the firm sees about 27% upside on average for its Buy-rated names and says about its Neutral-rated stocks that "sector bias/rotation supersedes fundamental headwinds."
• Deutsche Bank upgraded Freeport-McMoRan (FCX) to Buy from Hold with an unchanged price target of $47. The firm sees a "valuation disconnect" in the shares as well as potential U.S. policy catalysts.
  

Top 5 Downgrades:

• Wells Fargo downgraded MongoDB (MDB) to Equal Weight from Overweight with a price target of $225, down from $365, following the Q4 report. The shares traded down 16% after the company guided revenue and operating margin well below expectations, the firm tells investors in a research note.
• JPMorgan downgraded Campbell's (CPB) to Neutral from Overweight with a price target of $37, down from $48. The firm says Rao's sales and synergies have become better appreciated in the shares, Rao's growth has decelerated, and the Snacks margin story "has been delayed perhaps indefinitely."
• Summit Insights downgraded Marvell (MRVL) to Hold from Buy. The company's Datacenter end-market should continue to drive growth, and Marvell stands to benefit from port count expansion in the AI Server market segment and demand recovery in its traditional core Carrier and Enterprise Networking end-markets, but increased competition in the custom AI ASIC design market could result in further gross margin pressure, the firm tells investors in a research note.
• Morgan Stanley downgraded Brown-Forman (BF.B) to Underweight from Equal Weight with a price target of $32, down from $47. The company's sales and profit growth are likely to "remain muted" amid continued soft U.S. and global spirits demand, structural headwinds to alcohol consumption, tariff risk, and American whiskey oversupply, the firm tells investors in a research note.
• Roth MKM downgraded VersaBank (VBNK) to Neutral from Buy with a price target of $10.40, down from $22. The firm cites continued deceleration of Canada point of sale financing and a slower than expected U.S. receivable purchase program launch for the downgrade.

Top 5 Initiations:

• Cantor Fitzgerald initiated coverage of Robinhood (HOOD) with an Overweight rating and $69 price target. The firm says Robinhood is one of the most popular financial services platforms, particularly among younger generations.
• RBC Capital initiated coverage of Insulet (PODD) with an Outperform rating and $340 price target. Key opinion leader checks suggest upside to consensus/ estimates, driven by global Omnipod 5, the firm says.
• Deutsche Bank initiated coverage of Enlight Renewable (ENLT) with a Buy rating and $22 price target, implying upside of 30%. The firm likes the company's growth profile, saying it offers a "robust" pipeline of projects in the near to medium-term.
• D. Boral Capital initiated coverage of Aduro Clean Tech (ADUR) with a Buy rating and $50 price target. The firm says the company's Hydrochemolytic Technology platform is a patented, water-based chemical process that can economically transform low-value carbon feedstock into high-value outputs.
• Wedbush initiated coverage of Tourmaline Bio (TRML) with an Outperform rating and $42 price target. The firm is positive on the setup for Tourmaline Bio's pacibekitugm, and it estimates earliest potential pacibekitug market entry in late 2028 and peak revenue reaching over $1B.